Androgen therapy in women

Approximately 43% of women in the United States between the ages of 18 and 59 years experience sexual dysfunction. Hypoactive sexual desire disorder (HSDD) is characterized by the absence of sexual fantasies and desire for sexual activity. Male sexual dysfunction has been extensively researched, but there is less evidence addressing the treatment of HSDD in women, particularly with regard to the use of androgen therapy. There are no FDA-approved testosterone treatments for women, despite the fact that 4 million prescriptions have been written off-label for HSDD. This highlights the need for more research on safety, efficacy, side effects, and transference issues.